<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Parathyroid surgery for inherited syndromes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Parathyroid surgery for inherited syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Parathyroid surgery for inherited syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tina WF Yen, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tracy S Wang, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sally E Carty, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22965722"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary hyperparathyroidism (HPT) is a disorder of the parathyroid glands in which one or more of the glands secrete an excess amount of parathyroid hormone. Although most commonly a sporadic disease, primary HPT can be a part of an inherited genetic syndrome in a small subset of patients. These inherited syndromes include multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 4 (MEN4), hyperparathyroid-jaw tumor syndrome (HPT-JT), and familial isolated hyperparathyroidism (FIHPT). An inherited form of HPT should be suspected in younger patients, especially those with multiglandular disease, those with syndromic manifestations, and those with a family history of an endocrinopathy that is known to be associated with HPT [<a href="#rid1">1</a>]. </p><p>Parathyroid surgery for the treatment of inherited syndromes will be reviewed here. The inherited syndromes are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and  <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/z/d/html/2038.html" rel="external">"Primary hyperparathyroidism: Pathogenesis and etiology", section on 'Familial hyperparathyroidism'</a>.)</p><p class="headingAnchor" id="H22965750"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>The indications for parathyroidectomy are the same for patients with either sporadic or inherited forms of primary hyperparathyroidism (HPT) [<a href="#rid2">2-16</a>]. Parathyroidectomy is required to treat HPT in symptomatic patients (eg, nephrolithiasis) and is the preferred treatment in asymptomatic patients who meet the Fourth International Workshop on Asymptomatic Primary Hyperparathyroidism criteria  (<a class="graphic graphic_table graphicRef63054" href="/z/d/graphic/63054.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.)</p><p>In addition, the potential benefits of parathyroidectomy should be discussed with multiple endocrine neoplasia type 1 (MEN1) patients who have severe, medically refractory peptic ulcer disease or other symptoms due to a gastrinoma (ie, Zollinger-Ellison syndrome). Hypercalcemia worsens hypergastrinemia, which can exacerbate peptic ulcer disease. Successful parathyroidectomy may reduce gastrin secretion [<a href="#rid14">14,17</a>]. MEN1 patients with primary HPT may also have a greater reduction in both cortical and trabecular bone mass compared with patients with sporadic HPT [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management", section on 'Symptomatic disease'</a> and  <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management", section on 'Zollinger-Ellison syndrome'</a>.)</p><p class="headingAnchor" id="H22965799"><span class="h1">SURGICAL APPROACHES</span><span class="headingEndMark"> — </span>Surgical approaches to patients with inherited hyperparathyroidism (HPT) vary depending upon their individual syndromes [<a href="#rid8">8</a>]. The principles of parathyroid surgery, however, remain the same. </p><p class="headingAnchor" id="H587817546"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Since patients with an inherited form of primary HPT are at an increased risk of developing recurrent and persistent disease and may require multiple operations in their lifetime, the optimal surgical strategy requires a compromise between the relief of symptoms and avoidance of complications. The general principles include:</p><p class="bulletIndent1"><span class="glyph">●</span>Obtaining and maintaining eucalcemia for the longest possible duration</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding permanent hypoparathyroidism</p><p class="bulletIndent1"><span class="glyph">●</span>Minimizing other surgical complications, such as recurrent laryngeal nerve injury</p><p class="bulletIndent1"><span class="glyph">●</span>Facilitating future surgery for persistent/recurrent disease </p><p></p><p class="headingAnchor" id="H22965813"><span class="h2">MEN1</span><span class="headingEndMark"> — </span>For the initial treatment of multiple endocrine neoplasia type 1 (MEN1) patients with primary HPT, we perform a subtotal parathyroidectomy with intraoperative parathyroid hormone (PTH) monitoring. In patients who develop recurrent HPT, we perform either completion total parathyroidectomy with forearm autotransplantation or debulking of the parathyroid remnant.</p><p class="headingAnchor" id="H2060668875"><span class="h3">Initial parathyroidectomy</span></p><p class="headingAnchor" id="H596294465"><span class="h4">Surgical options</span><span class="headingEndMark"> — </span>For patients with MEN1, the choice of initial surgery includes subtotal (three and one-half glands) parathyroidectomy or total parathyroidectomy with nondominant forearm autotransplantation. Studies have evaluated the role of more limited initial resections (either resection of a single gland or unilateral clearance of both parathyroid glands) in patients for whom preoperative imaging demonstrates a concordant single focus of disease and intraoperative PTH levels drop adequately [<a href="#rid19">19-21</a>]. Although associated with short-term success, these studies have small sample sizes and limited long-term follow-up. One study with 89 patients and a median follow-up of 112 months reported a shorter time to recurrence and higher recurrence rate (21.3 versus 10.1 versus 4.4 percent, p = 0.03) among patients undergoing resection of one to two glands compared with those undergoing subtotal or total parathyroidectomy with autograft [<a href="#rid22">22</a>]. Given the high rates of persistent and recurrent HPT in patients with MEN1, resections that are less than subtotal are not advised [<a href="#rid23">23-29</a>].</p><p class="headingAnchor" id="H1306041764"><span class="h4">Choice of initial procedure</span><span class="headingEndMark"> — </span>We typically perform a subtotal (removal of 3 to 3.5 parathyroid glands) rather than total parathyroidectomy with autotransplantation [<a href="#rid16">16,30,31</a>]. The parathyroid gland remnant left in situ should be the smallest, most normal-appearing parathyroid gland and/or the gland that would be most accessible (eg, an anteriorly located inferior gland) at the time of reoperative surgery [<a href="#rid32">32</a>]. (See <a class="local">'Extent of resection'</a> below.)</p><p>We perform all parathyroid surgeries with intraoperative PTH monitoring. If, after subtotal resection, the intraoperative PTH value remains high, we preferentially resect additional tissue from the remaining remnant, if possible, rather than proceeding with total parathyroidectomy. If the intraoperative PTH value is &lt;10 pg/mL (in an assay whose normal range is approximately 10 to 72 pg/mL), we perform an immediate forearm autograft to prevent permanent hypoparathyroidism [<a href="#rid6">6,32</a>]. </p><p>Both subtotal and total parathyroidectomy have been shown to achieve high rates of normocalcemia (&gt;95 percent) [<a href="#rid8">8,17,24-27,33-37</a>]. Total parathyroidectomy with immediate autotransplantation results in a higher rate of postoperative hypoparathyroidism than subtotal parathyroidectomy (10 to 45 percent versus 10 to 25 percent) [<a href="#rid8">8,17,24-27,33,34,36,37</a>]. However, subtotal parathyroidectomy predisposes patients to a greater risk of complications associated with reoperative cervical exploration in cases of recurrent HPT.</p><p>In a small trial, 32 patients with MEN1 were randomly assigned to undergo either subtotal parathyroidectomy or total parathyroidectomy with autotransplantation [<a href="#rid35">35</a>]. After a mean follow-up of 7.5 years, similar proportions of patients in each group had transient (6 out of 17 versus 6 out of 15) or permanent hypoparathyroidism (2 out 17 versus 1 out of 15), developed recurrent HPT (4 out of 17 versus 2 out of 15), or required reoperation (4 out 17 versus 1 out of 15).</p><p class="headingAnchor" id="H2457896748"><span class="h4">Timing</span><span class="headingEndMark"> — </span>The timing of parathyroid surgery in young, asymptomatic MEN1 patients is controversial. Early parathyroidectomy could decrease the long-term detrimental effects of HPT, such as bone loss and nephrolithiasis [<a href="#rid23">23,34,38,39</a>], but predisposes patients to potential recurrences and reoperations. Delaying parathyroidectomy until the glands are more enlarged could make the surgery simpler and decrease the likelihood of persistent or recurrent disease that would necessitate reoperative surgery. The timing of surgery in MEN1 patients is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management", section on 'Asymptomatic disease'</a>.)</p><p class="headingAnchor" id="H2228718289"><span class="h4">Thymectomy</span><span class="headingEndMark"> — </span>In MEN1 patients with &lt;4 parathyroid glands identified at the time of surgery, the initial parathyroidectomy should include bilateral transcervical thymectomy, given the relatively high prevalence of supernumerary glands residing in the thymus in such patients [<a href="#rid23">23-25,33,40</a>]. Because transcervical thymectomy does not remove the entire thymus, patients are still at risk of developing neuroendocrine tumors, such as thymic carcinoid, after the procedure [<a href="#rid2">2,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a>.)</p><p class="headingAnchor" id="H1646551989"><span class="h3">Management of recurrent disease</span><span class="headingEndMark"> — </span>Recurrent HPT is detected in 20 to 70 percent of MEN1 patients within 8 to 14 years after their initial surgery [<a href="#rid17">17,23,24,26-28,42-45</a>]. Reoperative surgery in the setting of an inherited syndrome (mostly MEN1) can achieve surgical cure in 78 to 91 percent of cases [<a href="#rid27">27,28,45-47</a>]. </p><p>For patients who have a neck recurrence after subtotal parathyroidectomy, we perform either completion total parathyroidectomy with forearm autotransplantation or debulking of the parathyroid remnant. For patients who have a forearm recurrence from a previous autotransplantation, we perform excision or debulking of the forearm autograft. (See <a class="local">'Reoperative management'</a> below.)</p><p class="headingAnchor" id="H1952739712"><span class="h4">Localization of hyperfunctioning parathyroid tissue</span><span class="headingEndMark"> — </span>For patients with recurrent disease, identification of the source of disease is mandatory prior to reoperation. HPT can originate from one or more of three potential sources:</p><p class="bulletIndent1"><span class="glyph">●</span>Growth of remnant tissue in the neck following subtotal parathyroidectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Supernumerary or ectopic gland in the neck or mediastinum </p><p class="bulletIndent1"><span class="glyph">●</span>Forearm autograft hyperfunction</p><p></p><p class="headingAnchor" id="H423688635"><span class="h5">Casanova test</span><span class="headingEndMark"> — </span>For patients with a forearm autograft, we perform the Casanova test to rule out recurrence in the forearm autograft [<a href="#rid48">48</a>]. In this test, a baseline PTH value is drawn from the nongrafted arm. The grafted arm is then rendered ischemic for 10 minutes by using an Esmarch bandage before another PTH value is drawn from the nongrafted arm. Comparison of the two PTH values determines the source(s) of recurrent HPT as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive (arm recurrence) </strong>– Patients with forearm autograft-dependent recurrence demonstrate a drop in systemic PTH of more than 50 percent after 10 minutes of grafted arm ischemia. Recurrence attributed to autonomous function of parathyroid autografts occurs in 3 to 67 percent of patients, with the higher rate seen in inherited HPT patients [<a href="#rid49">49-52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative (neck recurrence)</strong> – If the PTH value after 10 minutes of grafted arm ischemia remains unchanged or decreases by no more than 20 percent, the source of recurrent disease is not in the arm and therefore presumed to be in the neck. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indeterminate</strong> – In the group of patients who have a PTH drop between 20 and 50 percent, the test is inconclusive. In this setting, imaging studies are needed to determine whether to re-explore the neck, the forearm autograft, or both. </p><p></p><p class="headingAnchor" id="H1848057723"><span class="h5">Imaging</span><span class="headingEndMark"> — </span>In patients who do not have a forearm autograft or who have a negative or indeterminant Casanova test, we perform imaging studies to localize all hyperfunctioning parathyroid tissue in the neck or chest prior to reoperative parathyroid surgery [<a href="#rid47">47</a>]. If a forearm autograft is present and the Casanova test is negative or indeterminate, the forearm should be included in a 99 Tc-labeled sestamibi scan to evaluate for hyperplasia of the autograft [<a href="#rid53">53</a>].</p><p>Available imaging modalities include 99 Tc-labeled sestamibi scan with single photon emission computed tomography (SPECT), ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), as well as invasive localization procedures such as angiography with venous sampling for PTH gradients or fine needle aspiration of suspected parathyroid tissue for PTH levels. </p><p>We typically obtain at least two imaging studies, including a cervical ultrasound. The best imaging study or combination of studies for persistent disease, however, varies with the institution and surgeon preference, and a significant percentage of enlarged glands may be missed by conventional imaging [<a href="#rid47">47</a>]. Two studies with concordant localization findings would be ideal prior to re-exploration. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a>.)</p><p class="headingAnchor" id="H2013952467"><span class="h4">Reoperative management</span><span class="headingEndMark"> — </span>Reoperative parathyroid surgery is challenging to perform and therefore should be reserved for surgeons who have experience managing patients with familial hyperparathyroidism. Prior to performing the reoperation, the surgeon must reconfirm the diagnosis of HPT and review all available operative reports, pathology reports, and imaging studies. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neck</strong> – For patients who have undergone an initial subtotal parathyroidectomy, we perform either completion total parathyroidectomy with forearm autotransplantation or debulking of the parathyroid remnant [<a href="#rid6">6,15</a>]. Debulking of the parathyroid remnant avoids the potential complications of forearm autografting [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Forearm</strong> – Patients with hyperfunctioning forearm autografts should undergo excision or debulking of their hyperfunctioning autograft under local anesthesia guided by intraoperative PTH monitoring.</p><p></p><p class="headingAnchor" id="H3921581169"><span class="h4">Nonoperative management</span><span class="headingEndMark"> — </span>Patients with persistent or recurrent HPT who are not surgical candidates due to comorbidities, multiple prior surgeries, or a lack of demonstrable disease on imaging are managed nonoperatively, which is discussed elsewhere [<a href="#rid15">15,23,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Poor surgical candidates'</a>.)</p><p class="headingAnchor" id="H22965820"><span class="h2">MEN2A</span><span class="headingEndMark"> — </span>Because many patients with multiple endocrine neoplasia type 2A (MEN2A) develop medullary thyroid cancer (MTC) early in life, they often have had prophylactic or therapeutic total thyroidectomy before they develop hyperparathyroidism. The best approach to parathyroid surgery in MEN2A patients depends upon whether they have had prior thyroid surgery. </p><p>Patients with MEN2A must be biochemically screened for pheochromocytoma prior to surgery. In patients with a diagnosed pheochromocytoma, adrenalectomy should be performed before thyroid or parathyroid surgery [<a href="#rid15">15,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2", section on 'Symptomatic disease'</a>.)</p><p class="headingAnchor" id="H3757761578"><span class="h3">Parathyroid preservation during prophylactic thyroidectomy</span><span class="headingEndMark"> — </span>Many patients with MEN2A have repeated neck operations (eg, thyroidectomy, central neck lymphadenectomy) for MTC, during which normal parathyroid glands can be removed or devascularized. In this setting, we typically autograft any devascularized or accidentally removed normal parathyroid tissue to prevent the development of hypoparathyroidism [<a href="#rid57">57</a>]. Parathyroid tissue can be autografted to the nondominant forearm or the sternocleidomastoid muscle, depending upon the patient's risk of developing primary HPT as follows (see  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Primary hyperparathyroidism'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have a high risk of developing HPT (MEN2A with a ret proto-oncogene [<em>RET</em>] mutation associated with a high incidence of HPT), parathyroid tissue should be autografted into the forearm. The forearm location simplifies the diagnosis and management of recurrent disease due to autograft hypertrophy [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have a low risk of developing HPT (sporadic MTC, multiple endocrine neoplasia type 2B [MEN2B], or MEN2A with a <em>RET</em> mutation that is rarely associated with HPT), parathyroid tissue can be autografted into the sternocleidomastoid muscle [<a href="#rid15">15</a>]. </p><p></p><p class="headingAnchor" id="H525937"><span class="h3">Parathyroidectomy with thyroidectomy</span><span class="headingEndMark"> — </span>In patients with MEN2A undergoing an initial prophylactic or therapeutic thyroidectomy with a known diagnosis of HPT, we suggest exploring all four parathyroid glands but removing only grossly enlarged glands, guided by intraoperative PTH monitoring [<a href="#rid15">15,30</a>]. If all four glands are enlarged, then we perform a subtotal parathyroidectomy (removal of 3 to 3.5 glands) with a forearm autograft. In patients who require repeated neck surgeries for MTC, early forearm parathyroid gland autografting may reduce the risk of subsequent permanent hypoparathyroidism [<a href="#rid15">15</a>].</p><p>Given the relatively mild course of HPT in MEN2A patients, many surgeons prefer a conservative resection in order to minimize postoperative hypocalcemia [<a href="#rid5">5,6,58</a>]. They avoid total parathyroidectomy unless preservation of a parathyroid remnant in situ is not possible or is not desirable because all four glands are obviously abnormal [<a href="#rid7">7,15</a>]. Other experts favor total parathyroidectomy because of its low recurrence rate. In a study of 119 MEN2A patients, persistent or recurrent HPT occurred in 9, 14, and 0 percent of patients who underwent selective, subtotal, and total parathyroidectomy, respectively, at five years [<a href="#rid3">3</a>]. In this study, total parathyroidectomy was not associated with a higher rate of postoperative hypocalcemia (20 percent with total resection versus 29 percent with selective or subtotal resection). </p><p class="headingAnchor" id="H525931"><span class="h3">Parathyroidectomy after thyroidectomy</span><span class="headingEndMark"> — </span>In MEN2A patients with prior thyroidectomy who develop primary HPT, we suggest performing a focused neck exploration guided by preoperative localization studies and resecting only hyperfunctioning parathyroid gland(s) aided by intraoperative PTH monitoring [<a href="#rid4">4-7,15,30,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/15031.html" rel="external">"Intraoperative parathyroid hormone assays"</a>.)</p><p class="headingAnchor" id="H3314344989"><span class="h2">MEN4</span><span class="headingEndMark"> — </span>There is a paucity of reports on cases with MEN4, which may represent a more restrictive phenotype (primary HPT and pituitary neuroendocrine tumors) similar to MEN1 but without a mutation in the <em>MEN1</em> gene [<a href="#rid60">60</a>]. Mutations have been reported in the <em>CDKN</em> genes, most commonly <em>CDKN1B</em>. The clinical phenotype includes a high frequency of primary HPT and may also include functional and nonfunctional pituitary, gastrointestinal, and pancreatic neuroendocrine tumors [<a href="#rid61">61,62</a>]. Currently, no guidelines exist on the management of MEN4-associated primary HPT, and indications for parathyroidectomy are similar to those for MEN1 [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H22965827"><span class="h2">HPT-JT</span><span class="headingEndMark"> — </span>Hypercalcemia in patients with hyperparathyroid-jaw tumor syndrome (HPT-JT) is due to single-gland disease in approximately 90 percent of cases [<a href="#rid64">64,65</a>]. Thus, we suggest performing bilateral neck exploration and selective parathyroidectomy with the removal of only grossly enlarged parathyroid gland(s), guided by intraoperative PTH monitoring, particularly if there are concordant preoperative localization findings [<a href="#rid8">8,30,64,66,67</a>]. </p><p>In one study, only 18 percent of patients who underwent selective parathyroidectomy developed recurrent disease due to metachronous single gland involvement after a mean disease-free interval of 13.7 years [<a href="#rid64">64</a>]. In such cases, the diagnosis of primary hyperparathyroidism should be confirmed biochemically, and indications for surgery should be reevaluated. Accurate localization studies are mandatory in patients undergoing reoperative surgery. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism", section on 'Reoperation for recurrent or persistent hyperparathyroidism'</a>.)</p><p>HPT-JT patients are at risk (15 to 20 percent) of developing parathyroid carcinoma [<a href="#rid65">65,67</a>]. When parathyroid carcinoma is suspected, an en bloc resection of the affected gland with adjacent involved tissues, including the ipsilateral thyroid lobe, should be performed when necessary [<a href="#rid67">67,68</a>]. The treatment of parathyroid carcinoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2042.html" rel="external">"Parathyroid carcinoma", section on 'Resectable disease'</a>.)</p><p class="headingAnchor" id="H22965834"><span class="h2">FIHPT</span><span class="headingEndMark"> — </span>The extent of parathyroidectomy for familial isolated hyperparathyroidism (FIHPT) is controversial as FIHPT is comprised of a spectrum of disease due to incomplete expression of <em>MEN1</em>, HPT-JT, or familial hypercalciuric hypercalcemia, or due to an activating <em>GCM2</em> mutation [<a href="#rid69">69</a>]. Patients with <em>GCM2</em>-associated primary HPT may have higher rates of multiple gland disease and parathyroid carcinoma and lower cure rates compared with those with sporadic disease [<a href="#rid70">70</a>]. </p><p>In our practice, all patients known to have the disorder preoperatively undergo a bilateral neck exploration. We treat patients with FIHPT linked to mutations in the <em>MEN1</em> or <em>GCM2</em> genes in a similar manner to MEN1 patients, with subtotal or total resection [<a href="#rid8">8,69-71</a>]. We treat patients with FIHPT linked to mutations in the cell division cycle 73 (<em>CDC73</em>/<em>HRPT2</em>) gene or unknown mutations similarly to HPT-JT patients, with selective resections of grossly enlarged parathyroid glands, guided by intraoperative PTH monitoring [<a href="#rid8">8,72,73</a>]. Other experts advocate for treating all FIHPT patients with aggressive surgery of subtotal or total resection [<a href="#rid74">74</a>]. </p><p class="headingAnchor" id="H22965862"><span class="h1">SURGICAL TECHNIQUES</span></p><p class="headingAnchor" id="H525131"><span class="h2">Anesthesia</span><span class="headingEndMark"> — </span>Since bilateral neck exploration is typically planned, the majority of parathyroidectomies are performed under general anesthesia. Focused exploration of a single parathyroid adenoma localized preoperatively can be carried out under local or regional anesthesia with sedation [<a href="#rid75">75-79</a>]. </p><p class="headingAnchor" id="H22965869"><span class="h2">Initial exposure</span><span class="headingEndMark"> — </span>Patient position, skin incision, and initial exposure in a standard parathyroidectomy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Positioning'</a> and  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Incision'</a> and  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Dissection'</a>.)</p><p class="headingAnchor" id="H22965876"><span class="h2">Exploring for missing glands</span><span class="headingEndMark"> — </span>Standard steps to explore for missing (fewer than four) parathyroid glands are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Missing gland'</a>.)</p><p>For patients with multiple endocrine neoplasia type 1 (MEN1) who typically have four-gland disease and a high risk of recurrence, it is important that all glands be identified. If visual exploration is unsuccessful, intraoperative differential venous parathyroid hormone (PTH) sampling of both internal jugular veins may help lateralize a hyperfunctioning gland to one side of the neck [<a href="#rid80">80,81</a>]. Venous sampling is typically performed with a 23 or 25 gauge needle and analyzed in real-time using an intraoperative PTH assay. Lateralization is defined by a greater than 5 percent difference between the two PTH values. Venous sampling is more sensitive for identifying hyperfunctioning superior parathyroid glands.</p><p>If a parathyroid gland is deduced or suspected to be intrathyroidal, a portion of the putative gland can be sent for frozen section, or an aspirate of the tissue can be diluted in a syringe containing 1 mL of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> for intraoperative PTH measurement. The presence of parathyroid tissue is confirmed if the parathyroid hormone value is greater than 1500 pg/mL [<a href="#rid82">82</a>]. If possible, empiric thyroidectomy should not be performed routinely without first confirming the presence of parathyroid tissue within the thyroid gland, as thyroidectomy significantly increases central neck scarring and risks devascularization of the remaining parathyroid glands. </p><p>If a hyperfunctioning parathyroid gland remains elusive despite all efforts, the procedure should be terminated. Reevaluation of the initial diagnosis and further imaging studies to localize a possible unidentified cervical or mediastinal parathyroid gland should be performed before attempting a reexploration at a later date. (See  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism", section on 'Reoperation for recurrent or persistent hyperparathyroidism'</a>.)</p><p class="headingAnchor" id="H450318"><span class="h2">Extent of resection</span><span class="headingEndMark"> — </span>At the time of parathyroidectomy, care should be taken to avoid seeding the neck with parathyroid tissue, which can cause parathyromatosis. Complete removal of a parathyroid gland without damaging the capsule can be achieved by gentle dissection and clipping of the vascular pedicle. Placing a large metallic clip across the parathyroid gland before cutting into the gland minimizes the risk for seeding when creating a parathyroid remnant [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H22965883"><span class="h3">Subtotal parathyroidectomy</span><span class="headingEndMark"> — </span>Subtotal parathyroidectomy removes three (or more) parathyroid glands and leaves a remnant of the fourth (or the last remaining) gland. The remnant size may depend on the size of the remaining in situ<em> </em>gland, but we prefer to leave an approximately 40 to 60 mg remnant. The remnant gland should be devoid of any nodules, if possible, to avoid recurrent hyperparathyroidism (HPT). The technique of subtotal parathyroidectomy is described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15041.html" rel="external">"Parathyroidectomy in end-stage kidney disease", section on 'Subtotal parathyroidectomy'</a>.)</p><p class="headingAnchor" id="H22965890"><span class="h3">Total parathyroidectomy</span><span class="headingEndMark"> — </span>Total parathyroidectomy resects all (four or more) glands. The technique of total parathyroidectomy is described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15041.html" rel="external">"Parathyroidectomy in end-stage kidney disease", section on 'Total parathyroidectomy with heterotopic autotransplantation'</a>.)</p><p class="headingAnchor" id="H22965897"><span class="h2">Transcervical thymectomy</span><span class="headingEndMark"> — </span>Up to 30 percent of patients with inherited HPT have enlarged supernumerary glands often found within the thymus. Thus, bilateral transcervical thymectomy should be performed in patients undergoing parathyroid surgery for inherited HPT when fewer than four parathyroid glands are identified. Transcervical thymectomy is performed with blunt dissection through the existing cervical incision without the need for a sternotomy. After mobilization of the cervical portion of the thymic tongue, traction can be applied to allow for resection of at least the upper part of the thymus bilaterally.</p><p class="headingAnchor" id="H22965904"><span class="h2">Autotransplantation</span><span class="headingEndMark"> — </span>For inherited HPT patients who require autotransplantation, autografts are typically placed into the brachioradialis muscle of the nondominant forearm, rather than the sternocleidomastoid muscle. Forearm autotransplantation avoids a potential cervical reoperation in case the autograft becomes the source of recurrent HPT [<a href="#rid83">83</a>]. </p><p>The parathyroid autograft is prepared by taking nonnodular parathyroid tissue (40 to 80 mg) and cutting it into approximately 20 pieces of 1 mm<sup>3</sup> sized fragments. A longitudinal incision is made over the brachioradialis muscle of the patient's nondominant arm, and the parathyroid fragments are placed within the muscle pocket(s) created by blunt dissection of the muscle. Each muscle pocket is then closed with nonabsorbable sutures after complete hemostasis. </p><p>Autografts can take up to two to four years to function [<a href="#rid23">23</a>]. Up to 40 percent of autografts ultimately fail, leaving the patient with permanent hypoparathyroidism unless cryopreserved parathyroid tissue is available [<a href="#rid23">23,24,46</a>].</p><p>Other complications of forearm autografting include parathyromatosis secondary to iatrogenic spillage of parathyroid tissue. Parathyromatosis can make debulking a forearm remnant technically difficult. An en bloc resection of the remnant potentially increases the risk of damaging the brachioradialis muscle and/or surrounding neurovascular bundles [<a href="#rid54">54</a>]. </p><p class="headingAnchor" id="H22965911"><span class="h2">Cryopreservation</span><span class="headingEndMark"> — </span>Approximately 10 to 15 percent of patients develop postoperative hypoparathyroidism due to either ischemic necrosis of the parathyroid remnant or early failure of an autograft. Permanent hypoparathyroidism can potentially be prevented if cryopreservation of parathyroid tissue at the time of the initial subtotal or total parathyroidectomy is performed. </p><p>There are several methods of cryopreservation. The traditional method is to place all excised parathyroid tissue in normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> solution at 4°C until the end of the operation. Tissue from the smallest and most normal-appearing (least nodular) gland is then divided into pieces of 1 mm<sup>3</sup>. Approximately 20 to 30 pieces are then stored in vials containing 1 mL of carrier medium (80 percent culture medium [RPMI-1640], 10 percent patient serum, and 10 percent <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a>). Using a programmable freezer, the vials are then cooled to -70°C to -80°C at a rate of 1° per minute and then further cooled to -196°C at a rate of 20°C per minute. Other methods of gradually decreasing the temperature of the parathyroid fragments have also been described. The parathyroid tissue is stored at -70°C in a freezer or at -196°C in liquid nitrogen.</p><p>When delayed autografting is performed, the vials containing the cryopreserved parathyroid fragments are placed in a 37°C water bath until the carrier medium is thawed. The fragments are then washed several times in RPMI-1640 at a temperature of 37°C to eliminate the toxicity of <a class="drug drug_general" data-topicid="8898" href="/z/d/drug information/8898.html" rel="external">dimethyl sulfoxide</a>. Typically, 20 fragments of parathyroid tissue are placed within brachioradialis muscle pockets after one such piece has been submitted for pathologic confirmation. </p><p class="headingAnchor" id="H526593"><span class="h2">Intraoperative PTH monitoring</span><span class="headingEndMark"> — </span>We favor the use of intraoperative PTH monitoring for all patients undergoing parathyroid surgery. While many patients with inherited forms of HPT require bilateral exploration, intraoperative PTH monitoring may help guide the extent of resection and may indicate the presence of supernumerary and/or ectopic parathyroid glands [<a href="#rid6">6,8,84</a>]. Intraoperative PTH monitoring can also allow for immediate autotransplantation of parathyroid tissue when PTH levels become too low (&lt;10 pg/mL). In addition, intraoperative PTH monitoring is helpful in reoperative parathyroid surgery [<a href="#rid31">31,46,47,85-91</a>]. </p><p>When properly followed, an established intraoperative monitoring protocol can provide assurance that all hyperfunctioning parathyroid tissue has been adequately excised before the surgical procedure is concluded. The optimal protocol in patients with inherited HPT syndromes is not defined. A 70 to 90 percent reduction in PTH levels has been proposed to indicate the removal of all hyperfunctioning glands in this patient population, which is more stringent than the Miami criterion (50 percent reduction) commonly used for patients with sporadic primary HPT [<a href="#rid23">23,45,92,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/15031.html" rel="external">"Intraoperative parathyroid hormone assays", section on 'Intraoperative PTH monitoring protocols'</a>.)</p><p class="headingAnchor" id="H22965948"><span class="h1">POSTOPERATIVE CARE</span><span class="headingEndMark"> — </span>Standard postoperative care after a parathyroidectomy has been described elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Postoperative care'</a>.)</p><p>Patients undergoing parathyroidectomy for inherited forms of hyperparathyroidism (HPT) should undergo long-term follow-up for surveillance of persistent or recurrent HPT and the development of associated endocrinopathies by a multidisciplinary team of endocrinologists, surgeons, and genetic counselors. (See  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'</a> and  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Screening for MEN2-associated tumors'</a>.)</p><p class="headingAnchor" id="H22965969"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Technical complications of parathyroid surgery (eg, bleeding, hematoma, or wound infection) typically occur in fewer than 5 percent of patients. Superior or recurrent laryngeal nerve injuries occur in fewer than 1 percent of patients. (See  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Complications'</a>.)</p><p>After parathyroid surgery, 10 to 15 percent of patients develop hypoparathyroidism that persists for more than six months. In these patients, any available cryopreserved parathyroid tissue should be transplanted, although delayed autotransplantation has a lower success rate compared with immediate autotransplantation (70 versus 100 percent) [<a href="#rid49">49,94-97</a>]. If cryopreserved parathyroid tissue is not available, calcium with vitamin D supplementation must be administered indefinitely. (See <a class="local">'Cryopreservation'</a> above and  <a class="medical medical_review" href="/z/d/html/15039.html" rel="external">"Parathyroid exploration for primary hyperparathyroidism", section on 'Postoperative hypocalcemia'</a>.)</p><p class="headingAnchor" id="H1922753004"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114502.html" rel="external">"Society guideline links: Parathyroid surgery"</a>.)</p><p class="headingAnchor" id="H22965990"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Primary hyperparathyroidism (HPT) is most commonly a sporadic disease but can be a part of inherited genetic syndromes, such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 4 (MEN4), hyperparathyroid-jaw tumor syndrome (HPT-JT), or familial isolated hyperparathyroidism (FIHPT). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The indications for parathyroidectomy are the same for patients with both sporadic and inherited forms of primary HPT. (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Symptomatic'</a> and  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Candidates for surgery'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical approaches to inherited HPT vary depending upon the individual syndromes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have MEN1, we suggest performing initial subtotal rather than total parathyroidectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Bilateral transcervical thymectomy may be performed when fewer than four parathyroid glands are identified at the time of the initial surgery. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with MEN1 who have a neck recurrence after subtotal parathyroidectomy, we perform either completion total parathyroidectomy with forearm autotransplantation or debulking of the parathyroid remnant. For patients who have a forearm recurrence from a previous autotransplantation, we perform excision or debulking of the forearm autograft. (See <a class="local">'Management of recurrent disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have MEN2A with a known diagnosis of HPT who are undergoing an initial prophylactic or therapeutic thyroidectomy, we suggest exploring all four parathyroid glands but removing only grossly enlarged glands, rather than performing a subtotal or total parathyroidectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Parathyroidectomy with thyroidectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For MEN2A patients with prior thyroidectomy who develop primary HPT, we suggest performing a focused neck exploration with resection of only abnormal parathyroid gland(s) rather than performing a subtotal or total parathyroidectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Preoperative parathyroid localization studies and intraoperative parathyroid hormone assays can be used to guide the focused neck exploration. (See <a class="local">'Parathyroidectomy after thyroidectomy'</a> above and  <a class="medical medical_review" href="/z/d/html/2069.html" rel="external">"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have HPT-JT, we suggest performing bilateral neck exploration but removing only grossly enlarged parathyroid gland(s), rather than performing a subtotal or total parathyroidectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with HPT-JT are at risk of developing parathyroid carcinoma, a condition that can require more extensive resection. (See <a class="local">'HPT-JT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The extent of parathyroid surgery for patients who have FIHPT is controversial and is influenced by the mutation each individual patient carries. (See <a class="local">'FIHPT'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We prefer to use intraoperative parathyroid hormone monitoring for all patients undergoing parathyroid surgery for inherited HPT. (See <a class="local">'Intraoperative PTH monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MEN2A should be biochemically screened for pheochromocytoma prior to parathyroid surgery. Adrenal surgery should precede parathyroid surgery in patients with a diagnosed pheochromocytoma. (See  <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2", section on 'Symptomatic disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many patients with MEN2A have repeated neck operations for medullary thyroid cancer, during which normal parathyroid glands can be removed or devascularized. In this setting, we typically autograft any devascularized or accidentally removed normal parathyroid tissue to prevent the development of hypoparathyroidism. (See <a class="local">'Parathyroid preservation during prophylactic thyroidectomy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3570.</a></li><li><a class="nounderline abstract_t">Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.</a></li><li><a class="nounderline abstract_t">Herfarth KK, Bartsch D, Doherty GM, et al. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 1996; 120:966.</a></li><li><a class="nounderline abstract_t">Mortenson MM, Evans DB, Lee JE, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. J Am Coll Surg 2008; 206:888.</a></li><li><a class="nounderline abstract_t">Raue F, Kraimps JL, Dralle H, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995; 238:369.</a></li><li><a class="nounderline abstract_t">Evans DB, Rich TA, Cote GJ. Surgical management of familial hyperparathyroidism. Ann Surg Oncol 2007; 14:1525.</a></li><li><a class="nounderline abstract_t">Akerström G, Stålberg P. Surgical management of MEN-1 and -2: state of the art. Surg Clin North Am 2009; 89:1047.</a></li><li><a class="nounderline abstract_t">Stålberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg 2009; 33:2234.</a></li><li><a class="nounderline abstract_t">Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003; 138:409.</a></li><li><a class="nounderline abstract_t">Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005; 15:531.</a></li><li><a class="nounderline abstract_t">Chen JD, Morrison C, Zhang C, et al. Hyperparathyroidism-jaw tumour syndrome. J Intern Med 2003; 253:634.</a></li><li><a class="nounderline abstract_t">Mizusawa N, Uchino S, Iwata T, et al. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 2006; 65:9.</a></li><li><a class="nounderline abstract_t">Sharma J, Weber CJ. Surgical therapy for familial hyperparathyroidism. Am Surg 2009; 75:579.</a></li><li><a class="nounderline abstract_t">Norton JA, Cornelius MJ, Doppman JL, et al. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987; 102:958.</a></li><li><a class="nounderline abstract_t">Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.</a></li><li><a class="nounderline abstract_t">Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.</a></li><li><a class="nounderline abstract_t">Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247:501.</a></li><li><a class="nounderline abstract_t">Marini F, Giusti F, Cioppi F, et al. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy. Cells 2021; 10.</a></li><li><a class="nounderline abstract_t">Versnick M, Popadich A, Sidhu S, et al. Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism. Surgery 2013; 154:101.</a></li><li><a class="nounderline abstract_t">Prichard RS, O'Neill CJ, Oucharek JJ, et al. Is focused minimally invasive parathyroidectomy appropriate for patients with familial primary hyperparathyroidism? Ann Surg Oncol 2012; 19:1264.</a></li><li><a class="nounderline abstract_t">Kluijfhout WP, Beninato T, Drake FT, et al. Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1. World J Surg 2016; 40:2964.</a></li><li><a class="nounderline abstract_t">Manoharan J, Albers MB, Bollmann C, et al. Single gland excision for MEN1-associated primary hyperparathyroidism. Clin Endocrinol (Oxf) 2020; 92:63.</a></li><li><a class="nounderline abstract_t">Lambert LA, Shapiro SE, Lee JE, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg 2005; 140:374.</a></li><li><a class="nounderline abstract_t">Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 2003; 134:858.</a></li><li><a class="nounderline abstract_t">Goudet P, Cougard P, Vergès B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Néoplasies Endocriniennes Multiples Study Group. World J Surg 2001; 25:886.</a></li><li><a class="nounderline abstract_t">Hubbard JG, Sebag F, Maweja S, Henry JF. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 2006; 141:235.</a></li><li><a class="nounderline abstract_t">Hellman P, Skogseid B, Oberg K, et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery 1998; 124:993.</a></li><li><a class="nounderline abstract_t">O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 1993; 114:1031.</a></li><li><a class="nounderline abstract_t">Nilubol N, Weinstein LS, Simonds WF, et al. Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure. Ann Surg Oncol 2016; 23:416.</a></li><li><a class="nounderline abstract_t">Udelsman R, Åkerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3595.</a></li><li><a class="nounderline abstract_t">Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016; 151:959.</a></li><li><a class="nounderline abstract_t">Yen TW, Wang TS. Subtotal parathyroidectomy for primary hyperparathyroidism. Endocr Pract 2011; 17 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">Thompson NW. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient. J Intern Med 1995; 238:269.</a></li><li><a class="nounderline abstract_t">Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 2007; 246:1075.</a></li><li><a class="nounderline abstract_t">Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 2014; 156:1326.</a></li><li><a class="nounderline abstract_t">Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg 2011; 35:1993.</a></li><li><a class="nounderline abstract_t">Tonelli F, Marini F, Giusti F, Brandi ML. Total and Subtotal Parathyroidectomy in Young Patients With Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism: Potential Post-surgical Benefits and Complications. Front Endocrinol (Lausanne) 2018; 9:558.</a></li><li><a class="nounderline abstract_t">Burgess JR, David R, Greenaway TM, et al. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 1999; 134:1119.</a></li><li><a class="nounderline abstract_t">Marini F, Giusti F, Tonelli F, Brandi ML. When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism. Front Endocrinol (Lausanne) 2018; 9:597.</a></li><li><a class="nounderline abstract_t">Powell AC, Alexander HR, Pingpank JF, et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery 2008; 144:878.</a></li><li><a class="nounderline abstract_t">Burgess JR, Giles N, Shepherd JJ. Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2001; 55:689.</a></li><li><a class="nounderline abstract_t">Rizzoli R, Green J 3rd, Marx SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 1985; 78:467.</a></li><li><a class="nounderline abstract_t">Burgess JR, David R, Parameswaran V, et al. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 1998; 133:126.</a></li><li><a class="nounderline abstract_t">Dotzenrath C, Cupisti K, Goretzki PE, et al. Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg 2001; 167:173.</a></li><li><a class="nounderline abstract_t">Thompson GB, Grant CS, Perrier ND, et al. Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Arch Surg 1999; 134:699.</a></li><li><a class="nounderline abstract_t">Kivlen MH, Bartlett DL, Libutti SK, et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 2001; 130:991.</a></li><li><a class="nounderline abstract_t">Keutgen XM, Nilubol N, Agarwal S, et al. Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. Ann Surg Oncol 2016; 23:701.</a></li><li><a class="nounderline abstract_t">Casanova D, Sarfati E, De Francisco A, et al. Secondary hyperparathyroidism: diagnosis of site of recurrence. World J Surg 1991; 15:546.</a></li><li><a class="nounderline abstract_t">Feldman AL, Sharaf RN, Skarulis MC, et al. Results of heterotopic parathyroid autotransplantation: a 13-year experience. Surgery 1999; 126:1042.</a></li><li><a class="nounderline abstract_t">Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Recurrent hyperparathyroidism due to parathyroid autografts: incidence, presentation, and management. Am Surg 1993; 59:178.</a></li><li><a class="nounderline abstract_t">Mallette LE, Blevins T, Jordan PH, Noon GP. Autogenous parathyroid grafts for generalized primary parathyroid hyperplasia: contrasting outcome in sporadic hyperplasia versus multiple endocrine neoplasia type I. Surgery 1987; 101:738.</a></li><li><a class="nounderline abstract_t">Wells SA Jr, Farndon JR, Dale JK, et al. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg 1980; 192:451.</a></li><li><a class="nounderline abstract_t">Kiernan CM, Grubbs EG. Surgical Management of Multiple Endocrine Neoplasia 1 and Multiple Endocrine Neoplasia 2. Surg Clin North Am 2019; 99:693.</a></li><li><a class="nounderline abstract_t">Melck AL, Carty SE, Seethala RR, et al. Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy. Surgery 2010; 148:867.</a></li><li><a class="nounderline abstract_t">Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:5644.</a></li><li><a class="nounderline abstract_t">VanderWalde LH, Haigh PI. Surgical approach to the patient with familial hyperparathyroidism. Curr Treat Options Oncol 2006; 7:326.</a></li><li><a class="nounderline abstract_t">Moley JF, Skinner M, Gillanders WE, et al. Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2. Ann Surg 2015; 262:641.</a></li><li><a class="nounderline abstract_t">van Heerden JA, Kent RB 3rd, Sizemore GW, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes. Surgical experience. Arch Surg 1983; 118:533.</a></li><li><a class="nounderline abstract_t">Philip M, Guerrero MA, Evans DB, et al. Efficacy of 4D-CT preoperative localization in 2 patients with MEN 2A. J Surg Educ 2008; 65:182.</a></li><li><a class="nounderline abstract_t">Frederiksen A, Rossing M, Hermann P, et al. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J Clin Endocrinol Metab 2019; 104:3637.</a></li><li><a class="nounderline abstract_t">Medina JE, Randolph GW, Angelos P, et al. Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes. Head Neck 2021; 43:3996.</a></li><li><a class="nounderline abstract_t">Nosé V, Gill A, Teijeiro JMC, et al. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocr Pathol 2022; 33:197.</a></li><li><a class="nounderline abstract_t">Marx SJ, Lourenço DM Jr. Familial Hyperparathyroidism - Disorders of Growth and Secretion in Hormone-Secretory Tissue. Horm Metab Res 2017; 49:805.</a></li><li><a class="nounderline abstract_t">Iacobone M, Masi G, Barzon L, et al. Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 2009; 394:817.</a></li><li><a class="nounderline abstract_t">Iacobone M, Camozzi V, Mian C, et al. Long-Term Outcomes of Parathyroidectomy in Hyperparathyroidism-Jaw Tumor Syndrome: Analysis of Five Families with CDC73 Mutations. World J Surg 2020; 44:508.</a></li><li><a class="nounderline abstract_t">Mehta A, Patel D, Rosenberg A, et al. Hyperparathyroidism-jaw tumor syndrome: Results of operative management. Surgery 2014; 156:1315.</a></li><li><a class="nounderline abstract_t">Torresan F, Iacobone M. Clinical Features, Treatment, and Surveillance of Hyperparathyroidism-Jaw Tumor Syndrome: An Up-to-Date and Review of the Literature. Int J Endocrinol 2019; 2019:1761030.</a></li><li><a class="nounderline abstract_t">Tonelli F, Marcucci T, Giudici F, et al. Surgical approach in hereditary hyperparathyroidism. Endocr J 2009; 56:827.</a></li><li><a class="nounderline abstract_t">Marx SJ. New Concepts About Familial Isolated Hyperparathyroidism. J Clin Endocrinol Metab 2019; 104:4058.</a></li><li><a class="nounderline abstract_t">El Lakis M, Nockel P, Guan B, et al. Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. Surgery 2018; 163:31.</a></li><li><a class="nounderline abstract_t">Perrier ND, Villablanca A, Larsson C, et al. Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism. World J Surg 2002; 26:907.</a></li><li><a class="nounderline abstract_t">Cetani F, Pardi E, Ambrogini E, et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 2006; 64:146.</a></li><li><a class="nounderline abstract_t">Iacobone M, Barzon L, Porzionato A, et al. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery 2007; 142:984.</a></li><li><a class="nounderline abstract_t">Sarquis MS, Silveira LG, Pimenta FJ, et al. Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 2008; 143:630.</a></li><li><a class="nounderline abstract_t">Miccoli P, Barellini L, Monchik JM, et al. Randomized clinical trial comparing regional and general anaesthesia in minimally invasive video-assisted parathyroidectomy. Br J Surg 2005; 92:814.</a></li><li><a class="nounderline abstract_t">Carling T, Donovan P, Rinder C, Udelsman R. Minimally invasive parathyroidectomy using cervical block: reasons for conversion to general anesthesia. Arch Surg 2006; 141:401.</a></li><li><a class="nounderline abstract_t">Pintaric TS, Hocevar M, Jereb S, et al. A prospective, randomized comparison between combined (deep and superficial) and superficial cervical plexus block with levobupivacaine for minimally invasive parathyroidectomy. Anesth Analg 2007; 105:1160.</a></li><li><a class="nounderline abstract_t">Black MJ, Ruscher AE, Lederman J, Chen H. Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: what are the advantages? Ann Surg Oncol 2007; 14:744.</a></li><li><a class="nounderline abstract_t">Allendorf J, DiGorgi M, Spanknebel K, et al. 1112 consecutive bilateral neck explorations for primary hyperparathyroidism. World J Surg 2007; 31:2075.</a></li><li><a class="nounderline abstract_t">Taylor J, Fraser W, Banaszkiewicz P, et al. Lateralization of parathyroid adenomas by intra-operative parathormone estimation. J R Coll Surg Edinb 1996; 41:174.</a></li><li><a class="nounderline abstract_t">Ito F, Sippel R, Lederman J, Chen H. The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing. Ann Surg 2007; 245:959.</a></li><li><a class="nounderline abstract_t">Perrier ND, Ituarte P, Kikuchi S, et al. Intraoperative parathyroid aspiration and parathyroid hormone assay as an alternative to frozen section for tissue identification. World J Surg 2000; 24:1319.</a></li><li><a class="nounderline abstract_t">Wells SA Jr, Ellis GJ, Gunnells JC, et al. Parathyroid autotransplantation in primary parathyroid hyperplasia. N Engl J Med 1976; 295:57.</a></li><li><a class="nounderline abstract_t">Tonelli F, Spini S, Tommasi M, et al. Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J Surg 2000; 24:556.</a></li><li><a class="nounderline abstract_t">Clerici T, Brandle M, Lange J, et al. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. World J Surg 2004; 28:187.</a></li><li><a class="nounderline abstract_t">Sugg SL, Krzywda EA, Demeure MJ, Wilson SD. Detection of multiple gland primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Surgery 2004; 136:1303.</a></li><li><a class="nounderline abstract_t">Cayo AK, Sippel RS, Schaefer S, Chen H. Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease. Ann Surg Oncol 2009; 16:3450.</a></li><li><a class="nounderline abstract_t">Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg 2008; 248:420.</a></li><li><a class="nounderline abstract_t">Weber CJ, Ritchie JC. Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration. Surgery 1999; 126:1139.</a></li><li><a class="nounderline abstract_t">Lew JI, Solorzano CC, Montano RE, et al. Role of intraoperative parathormone monitoring during parathyroidectomy in patients with discordant localization studies. Surgery 2008; 144:299.</a></li><li><a class="nounderline abstract_t">Jaskowiak NT, Sugg SL, Helke J, et al. Pitfalls of intraoperative quick parathyroid hormone monitoring and gamma probe localization in surgery for primary hyperparathyroidism. Arch Surg 2002; 137:659.</a></li><li><a class="nounderline abstract_t">Dackiw AP, Sussman JJ, Fritsche HA Jr, et al. Relative contributions of technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probe detection, and the rapid parathyroid hormone assay to the surgical management of hyperparathyroidism. Arch Surg 2000; 135:550.</a></li><li><a class="nounderline abstract_t">Nilubol N, Weisbrod AB, Weinstein LS, et al. Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy. World J Surg 2013; 37:1966.</a></li><li><a class="nounderline abstract_t">Cohen MS, Dilley WG, Wells SA Jr, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 2005; 138:1033.</a></li><li><a class="nounderline abstract_t">Herrera M, Grant C, van Heerden JA, Fitzpatrick LA. Parathyroid autotransplantation. Arch Surg 1992; 127:825.</a></li><li><a class="nounderline abstract_t">Saxe AW, Spiegel AM, Marx SJ, Brennan MF. Deferred parathyroid autografts with cryopreserved tissue after reoperative parathyroid surgery. Arch Surg 1982; 117:538.</a></li><li><a class="nounderline abstract_t">Edis AJ, Linos DA, Kao PC. Parathyroid autotransplantation at the time of reoperation for persistent hyperparathyroidism. Surgery 1980; 88:588.</a></li></ol></div><div id="topicVersionRevision">Topic 15040 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162666" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739416" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for diagnosis and therapy of MEN type 1 and type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957482" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18471717" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595174" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary hyperparathyroidism in multiple endocrine neoplasia type 2A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17285397" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Surgical management of familial hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19836484" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgical management of MEN-1 and -2: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19184636" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Familial parathyroid tumors: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686527" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029119" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755959" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hyperparathyroidism-jaw tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16817812" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655601" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Surgical therapy for familial hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2891201" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25810047" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723327" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376196" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34440663" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809488" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989662" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is focused minimally invasive parathyroidectomy appropriate for patients with familial primary hyperparathyroidism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402205" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626728" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Single gland excision for MEN1-associated primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841561" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668715" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572029" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Néoplasies Endocriniennes Multiples Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549687" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854574" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903001" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542588" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162669" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532368" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134873" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Subtotal parathyroidectomy for primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673858" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043113" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262224" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713580" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30319541" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Total and Subtotal Parathyroidectomy in Young Patients With Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism: Potential Post-surgical Benefits and Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522858" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30364322" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040992" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11894982" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2858157" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484721" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316400" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401818" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742328" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27464610" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1891942" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Secondary hyperparathyroidism: diagnosis of site of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598186" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Results of heterotopic parathyroid autotransplantation: a 13-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476157" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recurrent hyperparathyroidism due to parathyroid autografts: incidence, presentation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2884734" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Autogenous parathyroid grafts for generalized primary parathyroid hyperplasia: contrasting outcome in sporadic hyperplasia versus multiple endocrine neoplasia type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7425691" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31255200" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Surgical Management of Multiple Endocrine Neoplasia 1 and Multiple Endocrine Neoplasia 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800255" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671147" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16916493" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Surgical approach to the patient with familial hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26366543" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6132593" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes. Surgical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18571130" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of 4D-CT preoperative localization in 2 patients with MEN 2A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990521" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34541734" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35285003" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136674" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Familial Hyperparathyroidism - Disorders of Growth and Secretion in Hormone-Secretory Tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19529956" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31493194" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-Term Outcomes of Parathyroidectomy in Hyperparathyroidism-Jaw Tumor Syndrome: Analysis of Five Families with CDC73 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25444225" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hyperparathyroidism-jaw tumor syndrome: Results of operative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31929790" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical Features, Treatment, and Surveillance of Hyperparathyroidism-Jaw Tumor Syndrome: An Up-to-Date and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797826" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Surgical approach in hereditary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30848815" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : New Concepts About Familial Isolated Hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108698" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12016470" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16430712" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063086" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436011" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931654" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Randomized clinical trial comparing regional and general anaesthesia in minimally invasive video-assisted parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16618900" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Minimally invasive parathyroidectomy using cervical block: reasons for conversion to general anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898405" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A prospective, randomized comparison between combined (deep and superficial) and superficial cervical plexus block with levobupivacaine for minimally invasive parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122989" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Local/cervical block anesthesia versus general anesthesia for minimally invasive parathyroidectomy: what are the advantages?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768656" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : 1112 consecutive bilateral neck explorations for primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8763181" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Lateralization of parathyroid adenomas by intra-operative parathormone estimation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17522522" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The utility of intraoperative bilateral internal jugular venous sampling with rapid parathyroid hormone testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11038200" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intraoperative parathyroid aspiration and parathyroid hormone assay as an alternative to frozen section for tissue identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1272325" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Parathyroid autotransplantation in primary parathyroid hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787076" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14708048" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657591" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Detection of multiple gland primary hyperparathyroidism in the era of minimally invasive parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19760044" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Utility of intraoperative PTH for primary hyperparathyroidism due to multigland disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18791362" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598199" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Retrospective analysis of sequential changes in serum intact parathyroid hormone levels during conventional parathyroid exploration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18656639" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Role of intraoperative parathormone monitoring during parathyroidectomy in patients with discordant localization studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049536" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pitfalls of intraoperative quick parathyroid hormone monitoring and gamma probe localization in surgery for primary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807279" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Relative contributions of technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probe detection, and the rapid parathyroid hormone assay to the surgical management of hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23722465" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360388" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1524483" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Parathyroid autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7073473" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Deferred parathyroid autografts with cryopreserved tissue after reoperative parathyroid surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7423379" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Parathyroid autotransplantation at the time of reoperation for persistent hyperparathyroidism.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
